Argenx Advances Efgartigimod Into China With Zai Lab Pact
Selects Option Of $75m In Stock For Upfront
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.
